Agenda & Faculty, April 19-20, 2024
Day 1 Moderated by: Prithviraj Bose
07:30
Registration Opens
08:50
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I
09:00
![Jason Gotlib Jason Gotlib](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Jason-Gotlib-qcu941xt5z68d8fdfbae3qae9ep8m5mfiq1uer43y8.png)
Update on Systemic Mastocytosis
Jason Gotlib, MD - Stanford University School of Medicine, California
09:20
![Jason Gotlib Jason Gotlib](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Jason-Gotlib-qcu941xt5z68d8fdfbae3qae9ep8m5mfiq1uer43y8.png)
Workup and Management of Eosinophilia in 2024
Jason Gotlib, MD - Stanford University School of Medicine, California
09:40
![Andrew Kuykendall Andrew Kuykendall](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Andrew-Kuykendall-qcu93th9ggungqrnspmqzaf8wxuxovouhk6h39gni8.png)
Of Rux, Ropeg and Rusfertide – Treatment of PV comes of age
Andrew Kuykendall, MD - Moffit Cancer Center, Texas
10:00
Panel Discussion
10:30
Coffee Break
Session II
10:50
![abdulraheem-yacoub abdulraheem-yacoub](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/abdulraheem-yacoub-qi26g75gi1p58hciykg94p0j2n6h4fr75x137nx62o.jpg)
What’s happening in ET in 2024
Abdulraheem Yacoub, MD - University of Kansas, Kansas
11:10
![Lucia Lucia](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Lucia-qcu93z4alh2deejgvs2ie900h934z2b8ic3dyx8agw.png)
Current status of interferons in MPNs
Lucia Masarova, MD - MD Anderson Cancer Center, Texas
11:30
![Lucia (2) Lucia (2)](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Lucia-2-qcu93x8m7szsr6m76r9999h3ahcejo3ru2sf0db2tc.png)
Early/pre-fibrotic PMF – Diagnosis, Prognosis and Management
Pankit Vachhani, MD - The University of Alabama, Alabama
11:50
Panel Discussion
12:20
Independent Expert Discussion supported by GSK
13:05
Lunch Break
Session III
13:55
![Nikolai-Podolstev Nikolai-Podolstev](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Nikolai-Podolstev-qi26mev1om7dzobko95gm4k8gcju0efbcoanfipgxs.jpg)
Making sense of all the prognostic models for MF
Nikolai Podoltsev, MD - Yale School of Medicine, Connecticut
14:15
![Ruben Ruben](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Ruben-qcu93y6gen132sku19nvtr8jvv7rrd7i67fwhn9on4.png)
JAK inhibitors for MF – where we stand in 2024
Ruben Mesa, MD - Levine Cancer Institute, Charlotte, North Carolina
14:35
![Stephen_Oh Stephen_Oh](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Stephen_Oh-qdrsvqm1pyomsmixq1o7louudbspb8dl6k9eayh61a.jpg)
Management of Anemia in Myelofibrosis – Old and New Drugs
Stephen T. Oh, MD - Washington University, Missouri
14:55
Panel Discussion
15:15
Room refresh and exhibit viewing
Session IV
15:35
![](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2023/09/Prithviraj.png)
Novel mechanisms of drug action in MF
Prithviraj Bose, MD - MD Anderson Cancer Center, Houston, Texas
15:55
![Jeanne Jeanne](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Jeanne-qcu93qnqvyqshwvr96ev9t4v4s8u1sdnh680nfku0w.png)
Allogeneic Stem Cell Transplantation for MF
Jeanne Palmer, MD - Mayo Clinic, Arizona
16:15
![Naveen Pemmaraju Naveen Pemmaraju](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Naveen-Pemmaraju-qfc2eb2egxluybgwdlkd9jb6gciwirmd4l6ts09hc0.jpg)
Moving Beyond Spleen and Symptoms: Time for New Endpoints in MF?
Naveen Pemmaraju, MD - MD Anderson Cancer Center, Houston, Texas
16:35
Panel Discussion
16:55
Adjourn
08:00 Registration Opens
Day 2 Moderated by: Rami Komrokji, MD
Session V:
09:00
![Mrinal Patnaik Mrinal Patnaik](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Mrinal-Patnaik-qi5tfxk9toa5j68zidazhlpu0muym6b3y0c6uyzc9a.jpg)
“Pre MDS” CHIP and CCUS
Mrinal Patnaik, MD - Mayo Clinic, Arizona
09:20
![Sanam Sanam](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Sanam-qcu93l0pqyj2k93y63z3uuk3kh0mrlr9geb3rrt728.png)
Updates on MDS diagnosis and classification
Sanam Loghavi, MD - MD Anderson Cancer Center, Texas
09:40
![Naval Daver Naval Daver](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Naval-Daver-qihmqd0bsp3scczwcvx9kkihqhpceknf9li91020ge.jpeg)
Update on clinical trials in HR-MDS
Naval Daver, MD - MD Anderson Cancer Center, Texas
10:00
Panel Discussion
10:20
Coffee Break
Session VI
Debate 1: Moderated by: Rami Komrokji, MD
Luspatercept is the new standard of care as first line therapy for LR-MDS
10:40
![Yazan_Madanat Yazan_Madanat](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Yazan_Madanat-qlvbzyz8hnkparqxkndu927ntc8w6oe1uvwtlypyvi.jpg)
Yes
Yazan Madanat, MD - UT Southwestern Medical Center, Dallas, Texas
10:50
![](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2022/07/max-stahl-150x150.jpeg)
No
Maximilian Stahl, MD - Dana-Farber Cancer Institute, Boston, Massachusetts
11:00
Debate Discussion
11:10
![](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2022/07/Amer-Zeidan-300x300.jpg)
Measuring the clinical benefit of therapies in Lower and higher risk MDS
Amer Zeidan, MD - Northwestern University Feinberg School of Medicine, Illinois
11:30
![Michael_Savona Michael_Savona](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Michael_Savona-qihmjodn73yds6pfdzwru98hnundo2450ihy65yspa.jpg)
When and how to use Imetelstat for LR-MDS
Michael R. Savona, MD - Vanderbilt University Medical Center, Nashville, Tennessee
11:50
Panel Discussion
12:10
Industry supported independent expert discussion
12:55
Lunch Break & Group Photo
Session VII: Moderators: Rami Komrokji
13:45
![Rami Rami](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2023/09/Rami.png)
Controversies in managing del 5q: early treatment and impact of other somatic mutations
Rami Komrokji, MD - MD Anderson Cancer Center, Texas
14:05
![Uma Uma](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2023/09/Uma.png)
Treatment of Higher risk MDS patients not eligible for allogeneic stem cell transplant
Uma Borate, MD The Ohio State University, Ohio
14:25
![Rafael Bejar Rafael Bejar](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Rafael-Bejar-scaled-qi5thf52n8bhwy35tigpxq73vlivsx7t5div7qrwem.jpg)
How do I risk stratify MDS patients?
Rafael Bejar, MD - University of California, San Diego, California
14:45
Panel discussion
15:05
Independent expert discussion supported by Abbvie
15:50
Coffee Break
Session VIII
Fellows / Junior Debate 1: Moderated by: TBD
Treatment is needed prior to Allo-SCT
16:00
![Luis_Aguirre Luis_Aguirre](https://mpn-mds-us2024.md-education.com/wp-content/uploads/elementor/thumbs/Luis_Aguirre-qi5tkv7rpd1chh2xp03h2uvyagjc0ywdmfmyk9nxla.png)
Yes
Luis Aguirre, MD - Dana-Farber Cancer Institute, Boston, Massachusetts
16:10
![Somedeb Ball Somedeb Ball](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2022/07/Somedeb-Ball.png)
No
Somedeb Ball, MD - Vanderbilt University Medical Center, Nashville, Tennessee
16:20
Debate Discussion
16:40
![David David](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2023/09/David.png)
How do I manage TP53 MDS?
David Sallman, MD - Moffit Cancer Center, Texas
17:00
![](https://i.gyazo.com/2428416f276963032bd4c9b39cf76fb6.png)
Beyond allogeneic stem cell transplant in MDS: Immune therapies and CAR-T
Hany Elmariah, MD - Moffit Cancer Center, Florida
17:20
![](https://mpn-mds-us2024.md-education.com/wp-content/uploads/2022/07/Guillermo_Montalban_Bravo-150x150.png)
MDS/MPD
Guillermo Montalban Bravo, MD - MD Anderson Cancer Center, Houston, Texas